ACRES and GuideStar Clinical Trials Management to Partner
The Alliance for Clinical Research Excellence and Safety (ACRES) and GuideStar Clinical Trials Management to Partner on Site-Sustainability Standards, Global Site Network Registration, Site Optics and Third Party Accreditation Oversight.
GuideStar Clinical Trials Management, a company providing support services and strategies for clinical research programs around the United States, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector, non-profit organization building a multi-stakeholder-driven integrated global system for clinical research, today announced their partnership to expand site accreditation and uniformity across the clinical research community to promote and reward excellence.
As a Strategic Ally, GuideStar will collaborate with ACRES on its Site Accreditation Standards Initiative, a project to promote professionalism and sustainability among sites conducting research. The initiative-currently assembling teams across multiple performance domains including: patient and subject engagement and protection; site personnel; research integrity; facilities; information systems and data management; management and administration; as well as quality management-focuses on collecting and developing standards for research sites. It also is establishing independent third-party accreditation and offers opportunities for research sites to undergo self and peer evaluations.
GuideStar is knowledgeable in research operations from years of experience in the industry and working with nearly 100 health systems, hospitals and academic medical centers and will lend its expertise, including best practices, to the ACRES initiative. GuideStar will collaborate with other ACRES Allies in creating site-sustainability standards, registration of sites in a global network, site optics for self-review, and third party oversight of accreditation.
Shirley Trainor-Thomas, Chief Marketing Officer for GuideStar, expressed her enthusiasm about the partnership and the potential it brings. “As a clinical research services provider, the GuideStar team constantly strives to bring our clients guidance to optimize their research programs,” comments Trainor-Thomas. “By partnering with ACRES, we will contribute the solutions and best practices that promote sustainability for research sites around the globe. We are excited to join others in the industry in playing a role in this very important initiative for research sites and patients alike.”
Greg Koski, ACRES Co-founder and CEO, added, “There can be no global system for clinical research without well-prepared clinical research sites, sites of excellence. To create a world of high-performing professional sites we must invest in them and provide both incentives and rewards for their efforts. It is imperative for everyone that sites be given the tools and resources to help them achieve these goals, assistance which GuideStar is wonderfully qualified to give and we wholeheartedly welcome them to our ACRES group of Allies”.
ACRES
The Alliance for Clinical Research Excellence and Safety (ACRES) is a non-profit multi-sector alliance working in the public interest. It brings together diverse stakeholders across clinical research, harnesses their expertise to collaboratively build an open, integrated global system based in principles of Accountable Research™ and adapts lessons from industries that successfully implemented principles of systems and safety engineering, such as transportation, communications and information technology,
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
